Abstract | Healthy individuals can harbour microscopic tumours and dysplastic foci in different organs in an undetectable and asymptomatic state for many years. These lesions do not progress in the absence of angiogenesis or inflammation. Targeting both processes before clinical manifestation can prevent tumour growth and progression. Angioprevention is a chemoprevention approach that interrupts the formation of new blood vessels when tumour cell foci are in an indolent state. Many efficacious chemopreventive drugs function by preventing angiogenesis in the tumour microenvironment. Blocking the vascularization of incipient tumours should maintain a dormancy state such that neoplasia or cancer exist without disease. The current limitations of antiangiogenic cancer therapy may well be related to the use of antiangiogenic agents too late in the disease course. In this Review, we suggest mechanisms and strategies for using antiangiogenesis agents in a safe, preventive clinical angioprevention setting, proposing different levels of clinical angioprevention according to risk, and indicate potential drugs to be employed at these levels. Finally, angioprevention may go well beyond cancer in the prevention of a range of chronic disorders where angiogenesis is crucial, including different forms of inflammatory or autoimmune diseases, ocular disorders, and neurodegeneration.
Introduction
Cancer has been identified by the United Nations as a non-communicable disease posing a global health threat with considerable economic consequences.
1,2 The cost of cancer care in the USA alone is projected to rise from US$125 billion in 2010 to US$207 billion by 2020. 2 Although great strides have been made in reducing mortality from cardiovascular disease and other noncommunicable diseases through preventive efforts, cancer is still usually treated at advanced, often metastatic, disease stages. 3 Screening methods have improved prognosis for some cancers; 4 however, early detection is not yet possible for most malignancies, and the value of screening has been challenged for some tumours. 5 Targeted therapies are emerging as useful therapies, but treating all patients with these costly agents is not economically sustainable. 6, 7 As the world population exceeds 7 billion, cancer prevention clearly becomes an urgent goal to pursue.
Many cancers can be prevented by lifestyle changes, such as avoiding tobacco use, excessive UV exposure, infectious agents, poor dietary habits and obesity. 8 Behavioural studies suggest that promotion of healthy dietary habits and exercise is only moderately successful. 9 Thus, cancer prevention remains a difficult task. Preclinical evidence suggests that cancer prevention is feasible, but for the population at large the question is how.
It is estimated that half of men and a third of women will be diagnosed with a cancer in their lifetime. 10 The cancer diagnosis usually comes many years after the transforming events that spawned the cancer. Chemoprevention, the pharmacological prevention of cancer, was proposed over three decades ago, 11 but little has been invested to advance this life-saving approach, which should be inexpensive, non-toxic, and suitable for chronic administration. In this Review, we suggest a new consideration: limiting chemoprevention to tumour cells may be too specific. To be effective, cancer prevention should ideally impact on the organ microenvironment, boosting physiological defences against tumour development.
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Angiogenesis and angioprevention
Angiogenesis and inflammation are two host-dependent and interdependent hallmarks of cancer 13 that have an early permissive role in tumorigenesis ( Figure 1 ). Angioprevention is the term that we used 10 years ago when we proposed that angiogenesis inhibition was a common target of most cancer chemopreventive drugs.
14 Although epithelial cells that harbour mutations retain distinct, organ-specific phenotypes, endothelial cells are generally untransformed and a common target across many cancers. Increasing evidence supports the angio prevention approach in preclinical models as well as in epidemiological and clinical intervention studies in humans.
Judah Folkman first suggested that tumour dormancy could be maintained by preventing neovascularization of microscopic cancers. 15 However, the clinical validation of antiangiogenic therapy was done in the context of metastatic disease. Although antiangiogenic therapy has improved the standard of care for some cancers, its overall clinical benefit is modest for most patients, mainly observed in the form of prolonged progressionfree survival. 16, 17 In the setting of heavy disease burden, most patients treated with antiangiogenic agents eventually experience disease progression due to evolution of Similarly, in situ prostate cancer has been detected postmortem in 24% of men aged 60-70 years. 20 Microscopic thyroid cancers are estimated to be present in 98% of indivi duals by the age of 70. 21, 22 Yet, these cancers are diagnosed in only 2%, 8%, and <0.5%, respectively, in these age groups. The body's intrinsic ability to prevent tumour angiogenesis is one mechanism by which cancers are maintained in a prolonged dormant state. 23 Although it is not known which individuals with occult cancers will go on to develop clinical disease, angioprevention has the potential to avert this fate.
In the context of cancer, immune cells act as Janus-like components: on one side they can destroy cancer cells; on the other side they can promote tumour angiogenesis, growth and dissemination. [24] [25] [26] The presence of immune cells within tumours has been suggested to contribute to the carcinogenic and metastatic processes, 13, 27 and to tumour angiogenesis; [24] [25] [26] their polarization seems to determine clinical outcome. A typical example is macro phages: classically-activated M1 macro phages produce antiangiogenic Th1 cytokines (such as interleukin [IL]-12); by contrast, tumour-associated macrophages, M2 macrophages, Tie2-expressing macro phages and myeloid-derived suppressor cells produce Th2 cytokines, allow tissue reconstruction, growth promotion and angio genesis. 28, 29 Similar groupings have been proposed for poly morphonuclear neutrophils (PMNs) as either antitumour 'PMN1' (or N1) or pro tumour 'PMN2' (or N2) subsets that have a direct role in tumour angiogenesis. 26, 30 Protumour and proangiogenic polarization have been demonstrated for most tumour microenvironment immune cells including dendritic, mast, T and B cells. 25, 26, 28, 29, 31 Blocking chronic inflam mation can prevent protumour polarization and contribute to angioprevention.
Mechanisms of angioprevention
Vascular cell migration and invasion Inhibition of proteases involved in the degradation of the vascular basement membrane and extracellular matrix suppresses angiogenesis and metastasis. 32 Abnormal matrix remodelling by unchecked protease activity opens the way to sprouting vessels, by breaking the extracellular matrix and favouring detachment, attachment and spatial organization of endothelial cells. Targeting this remodelling is one mechanism of action attributed Key points ■ Angiogenesis and inflammation are host-dependent hallmarks of cancer that can be targeted using prevention approaches long before tumours initiate and progress ■ Several prescription and non-prescription drugs are already available for use in angioprevention, as well as a growing array of nutraceuticals ■ We propose four levels of angioprevention: I for the 'healthy' population; II for patients with increased risk of cancer; III for preneoplastic lesions; and IV for prevention of cancer recurrence ■ There are several successes in cancer prevention that demonstrate clinical feasibility and levels of intervention, from no to little to intense physician involvement ■ To avoid toxicity while maintaining efficacy, angioprevention needs to achieve a degree of angiogenesis control that is not excessively suppressive, such that healthy vascular function is maintained to the antiangiogenic activity of green tea 33 through inhibition of the matrix metallo proteinases (MMP)-2 and MMP-9. Inhibition of matrix remodelling can occur by direct binding as well as indirect mechanisms including downregulation of proteases and protease stimulators and upregulation of protease inhibitors. 34, 35 MMP inhibition has a role in the mechanism of action of numerous angiopreventive agents. 36, 37 Flavonoids such as fisetin, apigenin, and luteolin specifically and dose-dependently antagonize MMP-9 gene and protein expression in endothelial cells. 38 Organosulfur compounds such as sulforaphane and phenethyl isothiocyanate are naturally present in dietary cruciferous vege tables, including broccoli and Brussels sprouts. One key target of phenethyl isothiocyanate is protein kinase C, which leads to downstream inhibition of MMP-2 and MMP-9. 39 Eugenol (4-allyl-2-methoxyphenol), a component of basil, also inhibits angiogenesis through modu lation of MMP-2 and MMP-9; in addition, eugenol acts through modulation of VEGF, its receptor VEGFR-1, tissue inhibitor of metalloproteinases (CSC-21K, also known as TIMP-2) and RECK. 40 Other angiopreventive compounds, including hyperforin, curcumin, resveratrol, and sili binin, affect metalloproteases and other matrix proteolytic enzymes, thereby impacting on the migration and invasion of endothelial cells. 35, 41, 42 Endogenous angiogenesis inhibitors and hormones Many endogenous angiogenesis inhibitors reside within the host microenvironment, including thrombospondin-1, platelet factor 4, angiostatin and other plasminogen fragments, endostatin, tumstatin, alphastatin, arresten, canstatin, pigment epithelium-derived factor (PEDF), TIMP-2, ADAM-TS 9 and tetrahydrocortisol as well as some chemokines. 43 Induction of these inhibitors by drugs or diet can 'boost' innate vascular suppression and curb microscopic tumour growth (Figure 2 ). 43 Interferons (IFN) have long been known to inhibit angiogenesis. 44 Imiquimod is a topical immunomodulatory drug that is approved by the FDA for the treatment of actinic keratosis to prevent its progression to skin cancer. 45 This agent acts through activation of Toll-like receptor 7 (TLR7) and production of IFN-α, IFN-β, IFN-γ, IL-12 and IL-18; 46 repression of MMP activity, and inhibition of tumour angiogenesis. 47 As a preventative agent in women who have had oestrogen receptor-positive breast cancer, treatment with tamoxifen reduces the incidence of secondary breast cancer by more than 40%. 48 Tamoxifen has antitumour activity independent of its anti-oestrogen action that is associated with endostatin production. 49 A clinical study of early stage breast cancer showed that tamoxifen (20 mg/day) significantly increased endostatin levels in breast tissue and abdominal subcutaneous fat by 33%, while simultaneously lowering VEGF and angiogenin levels. 50 Endothelial cells are sensitive to the hormonal milieu, such as during the menstrual cycle, and hormonal mimetics and antagonists show antiangiogenic activities. 51 A diet high in phytoestrogens, such as genistein and enterolactone, slows breast cancer progression in a fashion similar to tamoxifen, 52 with inhibition of proinflammatory cytokines IL-1α and IL-1β that promote angiogenesis. Indeed, the phytoestrogens enterolactone, quercetin and curcumin alter oestrogen-dependent transcription of genes in breast cancer cells. 53 Inflammation and inflammatory angiogenesis Chronic inflammation, which promotes angiogenesis and is linked to the development of 30% of all cancers, 25 is a primary target for angioprevention. 24, 26 Chronic use of anti-inflammatory agents prevents a wide range of human tumours. [54] [55] [56] The angiopreventive agent resveratrol reduced neutrophil infiltration in mesenteric lymph nodes and lamina propria in a colon cancer model. 57 The signal transducer and activator of transcription (STAT) family member STAT3 is a central signalling hub for immune cells, 58 and is often activated in cancer cells, leading to expression of VEGF, IL-10 and IL-6, which in turn upregulates STAT3 signalling in endothelial and immune cell subsets in the tumour microenvironment. 58 Several angiopreventive phytochemicals-such as apigenin, luteolin, and myricetin-target the STAT3 pathway, 59 ,60 as well as other key mediators of inflammation, including the NF-κB, PI3K, TNF-α, and HIF-1α pathways. 41, 61 Cyclooxygenase-2 (COX-2) is another proinflammatory molecule that is overexpressed in many cancers, inclu ding breast, colorectal, lung, and prostate and pre neoplastic lesions, such as ductal carcinoma in situ, cervical intraepithelial neoplasia, prostatic intraepithelial neoplasia, Barrett's oesophagus, and actinic keratosis, but is not highly expressed in healthy tissues. 62 COX-2 promotes carcinogenesis as well as angiogenesis through both prostaglandin-related and non-prostaglandin-related mechanisms. 63 The angiogenic mechanisms include induction of MMP-2 and MMP-9, production of VEGF, bFGF, and PDGF, and enhancement of αvβ3-mediated angiogenesis. 62 COX-2 inhibition interferes with these Only after the angiogenic switch, driven by increasing inflammation, and many subsequent cycles of replication will a tumour become clinically detectable. At this point, it will have extensively progressed, is likely to have disseminated tumour cells and may already be metastatic. Angioprevention, which includes anti-inflammatory antiangiogenic mechanisms, needs to be started when a tumour is a dormant or hyperplastic foci or even before this stage, and sustained to maintain the tumour in this state. The observation that angioprevention efficacy increases as a function of time of application with angioprevention drugs, such as aspirin, is not surprising when seen in this context. These concepts must also be kept in mind when developing clinical trials.
events, 63 thus aspirin and COX-2 inhibitors are bona fide angiopreventive agents. VEGF, MMPs and NF-κB are also targets of the β-adrenergic receptor blocker propranolol that has been shown to be anti angiogenic, and is clinically active in infantile hemangiomas. 64 Apoptosis, autophagy, senescence and stem cells The induction of autophagy or forcing activated endothelial cells into a quiescent state is also an angio preventive mechanism. 65 Among chemopreventive compounds, the phytochemicals sulforaphane 66 and resveratrol 67 can activate pathways leading to autophagy. Microarray data suggest that some angioprevention agents, such as N-acetyl-cysteine and 9-cis-retinoic acid, induce a molecular profile in endothelial cells similar to that of in vitro senescence. 65, 68 Beyond microscopic tumours, cancer stem cells (also known as cancer initiating cells) reside in, and are dependent on, the tumour microvasculature. Angiogenesis inhibitors have been shown to decrease putative cancer stem cell numbers, 69 suggesting that angiopreventive treatments could not only halt tumour growth but might also restrict cancer stem cell expansion. 69 Metabolism and caloric restriction Reduction of caloric intake and energy restriction reduces cancer risk. 70 Pharmacological metabolism regulators are under investigation for cancer prevention. Agents such as 2-deoxyglucose (2-DG), antidiabetic agents targeting glucose metabolism (metformin, rosiglitazone and pioglitazone), and histone deacetylase inhibitors, all exhibit antiangiogenic activity. [71] [72] [73] The mTOR pathway controls protein metabolism in concert with AMPK and Akt; therefore, over-activation of mTOR can induce VEGF-mediated angiogenesis (Figure 3) . 74 The mTOR inhibitors, rapamycin, sirolimus, temsirolimus and everolimus (rapalogs) are in clinical use based on dual antiangiogenic and antitumour properties. 75 Rapalogs are undergoing clinical assessment for the secondary chemoprevention of skin cancer and secondary cancers in patients who are immunosuppressed following transplantation. 76, 77 Metformin, an AMPK stimulator, inhibits mTOR and demonstrates antiangiogenic activity in vitro and in vivo. [78] [79] [80] Among its unique mechanisms is the upregulation of PEDF, an endogenous angiogenesis inhibitor. 81 Redox stress is another key component of oncogenicinduced chronic inflammation. 13, [25] [26] [27] Oxygen radicals can activate endothelial cells and influence cytokine release and vascular permeability. 82 Antioxidants are widely proposed for cancer prevention, 83 and in endothelial cells an antioxidant response may restore redox homeostasis. 84 Many angiopreventive agents exert pleiotropic effects by inhibiting angiogenesis and inflammation mediated by redox-sensitive targets, such as NF-κB, Akt, mTOR ( Figure 3) . 85, 86 Because energy restriction and metabolic regulation have anti-inflammatory and angiosuppressive consequences, 84, 87, 88 another benefit of angioprevention could be weight control (Box 1).
Angioprevention in the clinic
Clinically, angioprevention maintains transformed cells in a dormant state and keeps the microenvironment healthy so that transformation is hampered despite Figure 2 | Angiogenesis is controlled by a balance of endogenous stimulators and inhibitors; in homeostasis, the sum of these effects is null. Stimuli, for example in wound healing, can tip the balance, at first in favour of angiogenesis, where many new vessels are formed, then towards antiangiogenesis, where excess vessels are pruned away. Some angioprevention approaches aim to boost endogenous inhibitor levels and/or lower stimulators. Cell polarization from protumour to antitumour phenotypes, and metabolic repression can also promote a microenvironment resistant to tumour vascularization and tumour expansion. Abbreviations: MMP , matrix metalloproteinase; ROS, reactive oxygen species; TIMP , tissue inhibitor of metalloproteinase.
promoting stimuli. We propose four distinct levels of angioprevention ( Figure 4) .
Level I
This level is aimed at cancer prevention in the general healthy population at 'lowest' risk of developing cancer. In these low-risk individuals, intervention must be safe with few, if any, adverse effects. Possible interventions include dietary factors and scientifically supported dietary supple ments, caloric restriction, and aspirin, which is already used to prevent heart attack or stroke.
Combinations of drugs or foods and nutritional supplements might have synergistic angiopreventive activity. 89 For level I angioprevention, regulatory approval might be unnecessary as long as the interventions are safe and suitable for general application.
Level II Level II angioprevention would be aimed at cancer prevention in individuals at moderate-to-high cancer risk. These include healthy persons with genetic abnormalities that are associated with a higher cancer risk (for example, BRCA1 and BRCA2 mutations, Li-Fraumeni syndrome and familial adenomatous polyposis), family history (any heritable cancer), occupational or lifestyle exposure (such as asbestos, toxins, tobacco and heavy alcohol consumption), immunosuppression (for example, transplan tation, or HIV) and/or metabolic syndromes (including diabetes). The higher cancer risk of individuals in this group justifies a higher risk tolerance for the angioprevention agents used than in level I. Metformin is a well-tolerated drug suitable for level II angioprevention 90 that is widely prescribed for type 2 diabetes and is potentially also usable for level I angioprevention. Difluoromethylornithine (an inhibitor of polyamine synthesis) and sulindac, 54 fenretinide and hormonal mimetics 91 also fall into the level II angioprevention category. Selected phytocompounds (curcumin, hyperforin, xanthohumol, and black raspberry extract) would also be appropriate, 3, 92 as well as synthetic triterpenoids, such as bardoxolone, which show potent antiangiogenic and anti-inflammatory activity. [93] [94] [95] Level III Individuals with pre-neoplastic lesions, such as skin actinic keratosis, oral leukoplakia, colon adenomas, cervical dysplasia, prostatic hypertrophy, and Barrett's oesophagus would be eligible for level III angioprevention strategies. The risk for progression to frank carcinoma warrants a more-aggressive angiopreventive approach, with a greater risk-to-risk-tolerance ratio. A number of prescription drugs with angiogenesis inhibitory properties are available, such as imiquimod (for skin cancer), finasteride (for prostate cancer), and celecoxib (for colon cancer). 96 For the latter, cardiac protective treatment is warranted. Level IV Level IV angioprevention aims to prevent disease recurrence in patients who have achieved cancer remission. An aggressive and sustained angiopreventive approach is necessary, since tumour cell dissemination is likely to exist. 98 Prevention of pathological angiogenesis is of paramount importance for durable cures. Angiopreventive interventions must potently suppress the 'soil' (microenvironment) as described by Steven Paget, so that the 'seed' (microscopic metastases) will not thrive. 99, 100 Level IV therapies include antiangiogenic cancer agents, such as tyrosine kinase inhibitors (axitinib, pazopanib, sorafenib, and sunitinib), mTOR inhibitors (everolimus, and temsirolimus), and certain chemotherapeutic drugs administered at low dose in a 'metronomic' schedule. 101 Long-term administration of bevacizumab in the adjuvant setting is currently under clinical investigation.
102,103
Regulatory issues, biomarker use Regulatory approval of pharmaceuticals for chemoprevention has proved challenging. Both finasteride and dutasteride have been shown in large clinical trials to decrease risk of prostate cancer by 25-35% in treated healthy men, for example, but both were denied FDA approval for cancer prevention, because of uncertainty for applicability in the general population. 104 The discovery of biomarkers for microscopic cancers may pave the way for monitoring the impact of angioprevention. 105 Recent discoveries of proangiogenesis and antiangiogenesis markers in the platelet proteome reflecting dormant cancers are now being translated to clinical studies. [106] [107] [108] Several microRNAs are highly expressed during angiogenesis, particularly miR-126 that targets VEGF. 109 Effects of phytocompounds on vascular microRNAs are coming to light, 110 including those with protective effects on endothelial cells. 111 MicroRNAs might also be a key source of biomarkers useful in angioprevention and cancer prevention in general. 112 Whether regulatory approval is required for clinical application of angioprevention remains an open question. Dietary and over-the-counter drug angioprevention may not even require physician involvement at level I, while interventions from level II to level IV will need to be prescribed by a clinician.
Successful angioprevention
Clinical trials that assess antiangiogenesis and angioprevention as an end point are underway (Table 1) , increasing the urgency for identifying biomarkers for angio genesis. 17 However, a number of chemopreventive angiogenesis inhibitory agents have shown clinical efficacy. Here, we describe selected compounds that demonstrate angiopreventive benefits.
Fenretinide
Several retinoids inhibit angiogenesis, including fenretinide. 113 A multicentre, randomized chemoprevention trial evaluated the effect of fenretinide on the incidence of contra lateral tumours in women with stage I breast cancer, showing a 35% reduction in second breast cancer incidence in premenopausal women and significantly (95% CI 0.000-0.522; P = 0.0327) lower incidence of ovarian cancer in the fenretinide arm. 114 An overall reduction by 17% (hazard ratio [HR] = 0.83; 95% CI 0.67-1.03) in second breast cancer incidence was observed with fenretinide after 14.6 years of follow up, along with a 38% (HR = 0.63; 95% CI 0.46-0.83) reduction in second breast cancer incidence in premenopausal women, 114 reaching 50% (P-age*treatment interaction = 0.023) in women aged 40 years or younger. Fenretinide may be active in BRCA mutation carriers, 113 and a randomized prevention trial is underway in women who are at high risk for breast and ovarian cancer.
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Metformin Metformin, widely used as a treatment for type 2 diabetes, 116 is well tolerated and associated with limited, transient side effects. Retrospective population studies showed a 21% reduced risk and improved survival for all cancers in patients with type 2 diabetes receiving metformin. 117, 118 The results were significant even after adjusting for BMI, a cancer risk factor. Conversely, diabetics treated with non-metformin regimens had an increased (1.36-1.42 fold) risk for cancer. 117 Another study demonstrated that patients taking metformin experienced a 62% risk reduction for pancreatic cancer. 119 Metformin upregulates circu lating levels of the antiangiogenic extracellular matrix molecule thrombospondin-1 (TSP-1) in insulinresistant obese women, likely one protective mechanism of action. 87 
Aspirin and NSAIDs
Observational studies of long-term use of aspirin or NSAIDs revealed a reduced risk of colon, breast, prostate and lung cancer. 56 Colon cancer and colon polyp
Box 1 | Angioprevention-not only in cancer
Pathological angiogenesis is a common denominator of many disorders, 96 suggesting that clinical angioprevention may provide benefits in a wide range of conditions beyond cancer. In contrast to cancer, other pathologies often show more dependence on specific angiogenic pathways, further enhancing targeted drug action; the success of angiogenesis inhibition in the treatment of 'wet' age-related macular degeneration (AMD) is an example. 145 This can be extended into the angioprevention realm. Epidemiological evidence suggests long-term non-steroidal anti-inflammatory drug (NSAID) use is associated with reduced risk of Alzheimer's disease, where pathological brain microvessels are characteristic. 146, 147 The AREDS (Age-related Eye Disease Study) formula supplementation 148 might implicate angioprevention in the neovascular form of AMD. Pathological angiogenesis driven by hypoxia and inflammation leads to joint destruction in patients with rheumatoid arthritis, 149, 150 where angioprevention may avert its progression. Angioprevention could even be used to prevent the growing epidemic of obesity, since controlling angiogenesis regulates adipose mass. [151] [152] [153] Genetic polymorphisms of VEGF are associated with childhood obesity, 154 and human studies have correlated BMI with inflammatory biomarkers (CRP) and angiogenesis (VEGF). 143 Green tea intake reduced visceral fat in adults by 6% over 12 weeks in a small, prospective, controlled trial; 155 other compounds such as synthetic triterpenoids are showing promise. 156 Finally, many angiopreventive compounds, including phytochemicals, are showing protective effects on the cardiovascular system, not only by inhibiting atherosclerosis through suppressing plaque neovascularisation, but also by preventing collateral damage during cancer chemotherapy, while often enhancing efficacy. 42 Combinatorial angioprevention regimens are a highly promising but untapped frontier.
formation have undergone extensive study, because they are frequent lesions, higher risk groups can be identified and treated, and regular colonoscopy can be used to establish an accurate end point for both colon polyps and cancer. Multiple studies have shown that aspirin and NSAIDs, in particular selective COX-2 inhibitors, reduce colonic adenoma formation. 54, 120 Three large trials have now shown that regular, long-term aspirin use does reduce cancer incidence. Two of these, studying aspirin for cardioprotection, 55, 121 showed that regular aspirin use, independent of dose, decreases incidence and mortality of numerous cancers, with even greater reduction for a subset of cancers, including colorectal, lung, and brain cancer. Long-term usage (>5 years) was needed for these differences to become evident. 55 A large trial in patients with Lynch syndrome at risk for colorectal cancer showed significant differences in colorectal cancer incidence for a subgroup of individuals using aspirin for at least 2 years. 122 Aspirin has antiangiogenic activity that is mediated through both COX-dependent and independent mechanisms. [123] [124] [125] Celecoxib, a selective COX-2 inhibitor and potent anti-inflammatory agent, suppresses angiogenesis and has been clinically validated as a prevention agent for both sporadic colon adenomas and familial adenomatous polyposis. 126, 127 To mitigate the cardiovascular toxicities of celecoxib, low circulating levels of C-reactive protein may identify patients for whom the risk-benefit ratio of celecoxib chemoprevention is favourable.
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A double-blind, controlled randomized trial of 240 individuals with actinic keratosis showed that treatment with celecoxib for 9 months had a 60% reduction in the mean number of basal-cell and squamous-cell skin cancers. 129 A combination of sulindac and 2-difluoromethylornithine also demonstrated a remarkable reduction in colon adenoma formation. 54 
Polyphenols
Green tea consumption is associated with a decreased risk of colon, prostate, lung, oesophageal, and other cancers; 3, 41, 130 catechins are usually considered to be the active agents. A double-blind, placebo-controlled study in men with high-grade prostatic intraepithelial neoplasia showed that consuming green tea catechins (600 mg/day, equivalent to 4-6 cups of tea/day) over 1 year reduced progression to prostate cancer from 30% in the placebo group to 3% in the treatment arm. 130, 131 A Japanese study in patients following removal of colon polyps demonstrated that consumption of polyphenols equivalent to 12 cups of tea/day reduced the risk of adenoma recurrence by 50%. 132 Preventive effects of green tea on precancerous oral and cervical lesions have been documented. 133, 134 Extensive literature has associated green tea catechins with the inhibition of several pathways and molecules related to angio prevention. Polyphenon E, a catechin-rich extract from green tea leaves is being evaluated in multiple clinical trials of prostate, bladder, oesophageal, lung, head and neck cancers, as well as leukaemia, and is already commercially available as a topical ointment.
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Curcumin targets numerous angiogenesis mediators and inhibitors, 86 with beneficial effects in wound healing, as well as antiangiogenic effects in cancer. Phase I-II clinical trials established that curcumin is well tolerated at doses up to 8 g/day without showing dose-limiting toxicity, 136, 137 and pharmacological manipulations are ongoing to increase bioavailability of the natural molecule. Consistent data suggest curcumin is a promising candidate for colorectal cancer prevention. Curcumin in combination with quercetin decreased aberrant crypt foci by 40% in a phase IIa trial, 138 and also decreased the incidence of colon adenomas in patients with familial adenomatous polyposis. 139 Preclinical evidence of resveratrol activity in colorectal cancer prevention prompted phase I studies to assess the pharmacokinetics, pharmacodynamics and safety of the drug or more bioavailable derivatives in healthy volunteers or cancer patients. 140, 141 Remarkably, a randomized double-blind crossover study in healthy obese men showed that resveratrol (150 mg/day for Figure 4 | Four levels of angioprevention. All humans are at risk for developing cancer. As risk level increases, there is greater tolerance of collateral effects to obtain more benefit. Low toxicity interventions can be continued throughout higher levels. Abbreviations: BPH, benign prostatic hyperplasia; mAb, monoclonal antibody; NSAID, non-steroidal anti-inflammatory drug.
REVIEWS
30 days) exerts caloric-restriction-like effects, improves lipid profiles and decreases inflammatory markers. 142 Considering that metabolic disorders are associated with pathological angiogenesis and chronic inflammation 143 and can be predisposing conditions for some cancers, 70 these results constitute an important premise for further clinical studies.
Conclusions
A decade after its initial proposal, angioprevention is becoming a clinical reality that further shifts how we approach oncological disease, and uses strategies suitable for healthy individuals as well as those at high risk for cancer. Compared with classic chemoprevention directed at cancer cells, the inhibition of angiogenesis and inflammation boosts anticancer defence mechanisms and provides protection against a broad spectrum of neoplasms. We propose four levels of angioprevention: level I for the 'healthy' population; level II for those with conditions associated with a raised risk of cancer; level III for treatment of preneoplastic lesions; and level IV for prevention of recurrence of overt cancer. Angioprevention at levels I and II must be fundamentally non-toxic. Angiogenesis is crucial for wound healing and reproductive function, so angioprevention must be titrated to suppress undesirable angiogenesis, but not subvert healthy endothelial maintenance or function. We compare this goal of physiologically compatible angioprevention to the 'Goldilocks Zone' concept used by cosmologists seeking planets where life forms may reside. 144 The term originated from the fairy tale about a child seeking porridge that is neither too hot nor too cold, but is 'just right' . Angioprevention needs to achieve a degree of angiogenesis control that is neither over exuberant nor dangerously suppressed, without interfering with the Goldilocks Zone of healthy vascular function. One point that can be made is that many efficacious angioprevention drugs have multiple targets, yet do not completely inhibit any single pathway. This may lead to lower toxicity when compared with most potent single-target drugs. Several natural backbones of phytochemicals, such as aspirin, have been modified and tested for anticancer or chemopreventive activity. Molecular homologues could be designed from a chemopreventive backbone to be more antiangiogenic and more suitable as angiopreventives. Synthetic chemistry and mo lecular tailoring may be used to design angiopreventive diet derivatives or pharmaceuticals.
Clinical trials are now underway to test the efficacy of angiopreventive molecules such as curcumin, artemisinin, resveratrol, genistein, synthetic triterpenoids, and isothiocyanates in neurological, cardiovascular degenerative diseases, and cancer at levels III and IV as defined in this article. Given the global health priorities facing societies today, and with the cancer pandemic in our sights, angioprevention and its clinical development is a concept whose time has arrived.
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